Stada Arzneimittel (ETR:SAZ) has earned an average rating of “Sell” from the seven analysts that are presently covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a sell recommendation and two have given a hold recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is €73.49 ($90.73).
Several brokerages have issued reports on SAZ. Nord/LB set a €74.40 ($91.85) price objective on Stada Arzneimittel and gave the company a “sell” rating in a research report on Wednesday, December 20th. Warburg Research set a €74.40 ($91.85) price objective on Stada Arzneimittel and gave the company a “sell” rating in a research report on Friday, March 9th. Cfra set a €70.00 ($86.42) target price on Stada Arzneimittel and gave the company a “sell” rating in a research note on Monday, March 12th. Independent Research set a €89.00 ($109.88) target price on Stada Arzneimittel and gave the company a “neutral” rating in a research note on Monday, March 12th. Finally, Commerzbank set a €66.25 ($81.79) target price on Stada Arzneimittel and gave the company a “sell” rating in a research note on Tuesday, December 26th.
SAZ traded up €0.36 ($0.44) during trading on Friday, hitting €84.26 ($104.02). The company’s stock had a trading volume of 48,044 shares, compared to its average volume of 51,761. Stada Arzneimittel has a 12 month low of €53.41 ($65.94) and a 12 month high of €90.24 ($111.41).
COPYRIGHT VIOLATION WARNING: “Brokerages Set Stada Arzneimittel (SAZ) Price Target at $73.49” was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://stocknewstimes.com/2018/04/25/brokerages-set-stada-arzneimittel-saz-price-target-at-73-49.html.
STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxone for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; Diclofenac for pain/inflammation; and Pantoprazole for gastric ulcer/reflux.
Receive News & Ratings for Stada Arzneimittel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stada Arzneimittel and related companies with MarketBeat.com's FREE daily email newsletter.